Bio Livestream: Neuron Gale Ignition Sale 13X+ Oversubscribed
Join us this Friday for a livestream with the founders of Neuron Gale, an IP Token from Cerebrum DAO developing a novel treatment to fight brain inflammation using galectin-3 inhibition.
Seven hours into the 24-hour sale, GALE is already 7X oversubscribed with roughly $350K committed.
With the GALE sale concluding Friday Nov 21 at 11am UTC, there's still time to participate.
→ Join the GALE Ignition Sale: https://app.bio.xyz/ipts/neuron-gale
We'll be streaming live with the founders of GALE as the Ignition Sale concludes and the token goes live for open market trading.
More about Neuron Gale
Galectin-3 is a glycan-binding protein identified as a key regulator of neuroinflammation in Alzheimer’s disease. The research potential for AD is clear:
AD patients have significantly increased galectin-3 levels
Mice without galectin-3 show less amyloid plaque deposition and better cognitive function
No potent galectin-3 inhibitors currently pass the blood-brain barrier
GALE will infuse a highly specific galectin-3 inhibitor directly into the brains of AD mice over four weeks, monitoring effects on neuroinflammation and plaque deposition.
If successful, this validates galectin-3 as a target for pharmacological intervention. It could yield results not just for AD but for an array of neurodegenerative diseases.
The team
The project is led by key contributors of the Cerebrum DAO team:
Dr. Maryna Polyakova: Neuroscientist and lecturer at HTW Berlin, University of Leipzig, and Max-Planck Research School. Uses neuroimaging, neuropsychological testing, and machine learning to improve early diagnostics. Leads the Neurotech Tree project at Foresight Institute, building a new roadmap for the future of neurotechnology.
Dr. Peter Groenen: Industry executive with deep expertise in pharmaceutical R&D, specializing in translational science and biomarker integration. Experienced in driving projects from early research to late-stage development, collaborating with academia, industry, and regulatory bodies to accelerate therapeutic innovation.
The opportunity
The brain health market is valued in the trillions annually, with 150 million AD cases expected globally by 2050. Current treatments are minimally effective at best.
Galectin-3 is a novel target in AD. A disease-modifying inhibitor with a compelling safety profile could attain blockbuster drug status, especially for early-stage or pre-symptomatic populations.
Roadmap
Q1 2026
In vivo proof-of-concept in mouse AD model using Alzet pump with galectin-3 inhibitor
Brain analysis via ELISA/Western Blot measuring inflammation markers and Aß42 levels
Q2 2026
Immunohistochemistry analysis: plaque load and microglia analysis (Iba1, Gal3)
Q3 2026
Complete study data analysis combining all brain analysis data to identify clear inhibitory effects on AD descriptors
Milestone funding
GALE uses Bio Protocol’s new milestone-based funding mechanism. Funds unlock as market cap milestones are reached and maintained:
Initial Raise: $50K
Starting FDV: $500K FDV